Open access · US-GOV via ClinicalTrials.gov Clinical trial

Investigation of AC-11® Supplementation in Reversing Epigenetic Markers of Biological Aging Including Those Related to Telomere Length

Authors not listed

TruDiagnostic · 2021

Telomere attrition Epigenetic alterations Human Randomized controlled trial

Abstract

This is a prospective non-randomized clinical study of 24 patients to evaluate the effects of the AC-11®. The study will evaluate the effectiveness of the supplement's ability to reverse epigenetic markers of biological age. The duration of the study will be 6 months.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-15 MST

Cite this

APA

Anonymous. (2021). Investigation of AC-11® Supplementation in Reversing Epigenetic Markers of Biological Aging Including Those Related to Telomere Length. <em>TruDiagnostic</em>. https://clinicaltrials.gov/study/NCT05310123

Vancouver

Anonymous. Investigation of AC-11® Supplementation in Reversing Epigenetic Markers of Biological Aging Including Those Related to Telomere Length. TruDiagnostic. 2021.

BibTeX

@misc{anon2021Invest, title = {Investigation of AC-11® Supplementation in Reversing Epigenetic Markers of Biological Aging Including Those Related to Telomere Length}, author = {Anonymous}, journal = {TruDiagnostic}, year = {2021}, }